Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12			
Name	of entity		
HU	B24 Limited		
ABN			
87 1	24 891 685		
Par	the entity) give ASX the follow t 1 - All issues nust complete the relevant sections (a	Č	
1	⁺ Class of ⁺ securities issued or to be issued	1.	Issue of Fully Paid Ordinary shares (FPO).
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1.	Issue of 31,669 FPO.
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible*	1.	The FPO are issued on the same terms as existing issued FPO of HUB24 Limited and are subject to sales restrictions of up to 24 months.

price

conversion)

securities, the conversion

dates

and

Appendix 3B Page 1 ME_134645333_2

⁺ See chapter 19 for defined terms.

Do the +securities rank equally in Yes, the FPO will rank equally with the all respects from the date of existing FPO. allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment The FPO 5 Issue price or consideration are issued as the result of performance consideration relating to the previous acquisition of Agility Applications, in accordance with the purchase agreement: 31,669 FPO at \$12.9849 per FPO (20 day VWAP to 31 December 2018). 6 Purpose of the issue The FPO are issued as the result of performance (If issued as consideration for the consideration relating to the previous acquisition of assets, clearly acquisition of Agility Applications, in identify those assets) accordance with the purchase agreement. Is the entity an ⁺eligible entity that No. 6a has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed Number of +securities issued 6c N/A without security holder approval under rule 7.1 Number of +securities issued with 6d N/A security holder approval under rule

7.1A

⁺ See chapter 19 for defined terms.

	·			
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A		
6f	Number of securities issued under an exception in rule 7.2	31,669 FPO.		
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A		
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Remaining capacity LR 7.1 – 9,349,412		
7	⁺ Issue date	29 March 2019		
	- r			
		Number		+Class
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	62,329,415		FPO
		Number	+Cla	ass
9	Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)	160,000		ions (exercisable at \$0.98 n expiring on 17 October 9).
		210,000		ions (exercisable at \$2.46 n expiring on 14 October 0).
		150,000		ions (exercisable at \$2.46 n expiring on 7 December

2020).

⁺ See chapter 19 for defined terms.

	1
50,000	Options (exercisable at \$3.98 each expiring on 30 March 2021).
356,893	Options (exercisable at \$4.46 each expiring on 29 November 2021).
50,000	Options (exercisable at \$5.17 each expiring on 29 November 2021).
116,829	Performance Rights (nil exercise price each expiring on 29 November 2031).
34,247	Options (exercisable at \$6.25 each expiring on 21 August 2022).
11,211	Performance Rights (nil exercise price each expiring on 21 August 2032).
327,422	Options (exercisable at \$7.09 each expiring on 11 October 2022).
100,213	Performance Rights (nil exercise price each expiring on 11 October 2032).
78,077	Options (exercisable at \$7.09 each expiring on 5 December 2022).
23,897	Performance Rights (nil exercise price each expiring on 5 December 2032).
257,851	Options (exercisable at \$12.04 each expiring on 7 September 2023).
70,889	Performance Rights (nil exercise price each expiring on 7 September 2033).

⁺ See chapter 19 for defined terms.

12,000	Options (exercisable at \$12.04 each expiring on 7 September 2023).
4,000	Performance Rights (nil exercise price each expiring on 7 September 2033).
30,000	Options (exercisable at \$11.73 each expiring on 7 September 2023).
10,000	Performance Rights (nil exercise price each expiring on 7 September 2033).
51,186	Options (exercisable at \$12.04 each expiring on 12 December 2023).
486,053	Performance Rights (nil exercise price each expiring on 12 December 2033).
24,667	Options (exercisable at \$13.44 each expiring on 12 December 2023).

trust, distribution policy) on the increased capital (interests)

Dividend policy (in the case of a Final dividend payable October, Interim dividend payable April.

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	⁺ Class of ⁺ securities to which the offer relates	N/A
15	*Record date to determine	N/A

Appendix 3B Page 5 ME_134645333_2

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with.	N/A
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A

⁺ See chapter 19 for defined terms.

29	Date rights trading will end (if applicable)	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Despatch date	N/A
	3 - Quotation of securitie	
You nee	d only complete this section if you are app	plying for quotation of securities
34	Type of securities (tick one)	
(a)	Securities described in Part 1	
(b)	All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entiti	es that have ticked box 34(a)	
Addit	ional securities forming a new cla	ass of securities
Tick to docume	indicate you are providing the informa nts	tion or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	

 $\begin{array}{c} \text{Appendix 3B Page 7} \\ \text{ME_134645333_2} \end{array}$

⁺ See chapter 19 for defined terms.

37	A copy of any trust deed for the	additional *securities	
Entitie	es that have ticked box 34(b)		
38	Number of securities for which +quotation is sought	N/A	
39	Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state:	N/A	
	 the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now Example: In the case of restricted securities, end of	N/A	
	example: in the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)		
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in clause 38)	Number N/A	+Class N/A

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 29 March 2019

(Company Secretary)

Print name: Mark Goodrick

Appendix 3B Page 9
ME_134645333_2

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	61,588,666	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	740,749	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ordinary securities that became fully paid in that 12 month period		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	62,329,415	

⁺ See chapter 19 for defined terms.

"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	9,349,412
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Nil
• Under an exception in rule 7.2	
Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	Nil
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining
pracement capacity arraor rate in	
	9,349,412
"A" x 0.15 Note: number must be same as shown in	9,349,412
"A" x 0.15 Note: number must be same as shown in Step 2	9,349,412 Nil
"A" x 0.15 Note: number must be same as shown in Step 2 Subtract "C" Note: number must be same as shown in	
"A" x 0.15 Note: number must be same as shown in Step 2 Subtract "C"	

⁺ See chapter 19 for defined terms.

Appendix 3B Page 11

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	N/A	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	N/A	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	N/A	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	N/A	
Note: number must be same as shown in Step 2		
Subtract "E"	N/A	
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	N/A	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 13 ME_134645333_2

⁺ See chapter 19 for defined terms.